Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1, randomized, double-blind, dose-escalation cohort study to evaluate the safety, tolerability and pharmacokinetics of a single intravenous infusion of MGAWN1, a neutralizing, humanized, monoclonal antibody (IgG [immunoglobulin] 1K) to West Nile virus, in healthy adults

Next Previous
Trial Profile

A phase 1, randomized, double-blind, dose-escalation cohort study to evaluate the safety, tolerability and pharmacokinetics of a single intravenous infusion of MGAWN1, a neutralizing, humanized, monoclonal antibody (IgG [immunoglobulin] 1K) to West Nile virus, in healthy adults

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 23 Feb 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MGAWN1 (Primary)
  • Indications West Nile virus infections
  • Focus Adverse reactions; Pharmacokinetics
  • Acronyms CP-MGAWN1-01
  • Sponsors MacroGenics

    • Most Recent Events

    • 29 Mar 2010 Results published in Antimicrobial Agents and Chemotherapy.
    • 13 Jul 2009 Status changed from active, no longer recruiting to completed according to Macrogenics media release.
    • 25 Oct 2008 Results presented at ICAAC-IDSA 2008.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top